EC approves Alprolix for the treatment of haemophilia B
Swedish Orphan Biovitrum AB (Sobi) and Biogen have announced that the European Commission (EC) has approved Alprolix (rFIXFc) for the treatment of haemophilia B and maintained its orphan designation.
Click on this link for more information.
